Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

Why is Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of 9.49% and Operating profit at 6.57% over the last 5 years

Flat results in Mar 26

INTEREST(HY) At CNY 0.43 MM has Grown at 11.73%
DEBT-EQUITY RATIO (HY) Highest at -47.67 %
INVENTORY TURNOVER RATIO(HY) Lowest at 0.79 times

With ROE of 14.93%, it has a fair valuation with a 3.60 Price to Book Value

Over the past year, while the stock has generated a return of 12.59%, its profits have risen by 36.3% ; the PEG ratio of the company is 0.7
At the current price, the company has a high dividend yield of 1.2

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

-7.39%

0.13

41.23%

China Shanghai Composite

8.25%

1.20

14.07%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

9.49%

EBIT Growth (5y)

6.57%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.53

Sales to Capital Employed (avg)

0.39

Tax Ratio

14.01%

Dividend Payout Ratio

34.36%

Pledged Shares

Institutional Holding

ROCE (avg)

33.71%

ROE (avg)

15.88%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

4.07

EV to EBIT

23.60

EV to EBITDA

21.35

EV to Capital Employed

6.91

EV to Sales

9.05

PEG Ratio

0.75

Dividend Yield

1.03%

ROCE (Latest)

29.30%

ROE (Latest)

14.93%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

9What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CNY 396.16 MM

ROCE(HY)

Highest at 16.48%

RAW MATERIAL COST(Y)

Fallen by -6.14% (YoY

CASH AND EQV(HY)

Highest at CNY 2,757.08 MM

DEBTORS TURNOVER RATIO(HY)

Highest at 4.02 times

PRE-TAX PROFIT(Q)

At CNY 130.26 MM has Grown at 55.5%

NET PROFIT(Q)

At CNY 117.69 MM has Grown at 59.03%

-5What is not working for the Company

INTEREST(HY)

At CNY 0.43 MM has Grown at 11.73%

DEBT-EQUITY RATIO (HY)

Highest at -47.67 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 0.79 times

Here's what is working for Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

Operating Cash Flow

Highest at CNY 396.16 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Pre-Tax Profit

At CNY 130.26 MM has Grown at 55.5%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit

At CNY 117.69 MM has Grown at 59.03%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

Cash and Eqv

Highest at CNY 2,757.08 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debtors Turnover Ratio

Highest at 4.02 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -6.14% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

Interest

At CNY 0.43 MM has Grown at 11.73%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Debt-Equity Ratio

Highest at -47.67 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Inventory Turnover Ratio

Lowest at 0.79 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Non Operating Income

Highest at CNY 0.27 MM

in the last five periods

MOJO Watch

Increased income from non business activities may not be sustainable

Non Operating income